November 2007
Worldwide Biotech;Nov2007, Vol. 19 Issue 11, p7
Trade Publication
The article reports that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) is nearing regulatory decision on Rapinyl, a drug for acute pain treatment from Orexo. The first indication of Rapinyl is breakthrough pain in cancer. The drug is based on Orexo's unique proprietary technology for sublingual administration, where a tablet is placed under the tongue and rapidly disintegrates into ordered mucoadhesive units of the active substance, according to the article.


Related Articles

  • OREXO/PROSTRAKAN EXTEND LICENSING PACT FOR RAPINYL (ABSTRAL).  // Worldwide Biotech;Sep2008, Vol. 20 Issue 9, p2 

    The article reports on the extension of the European licensing agreement between Swedish pharmaceutical company Orexo AB and Scottish specialty pharmaceutical company ProStrakan Group PLC. The agreement involves the drug Rapinyl for breakthrough cancer pain and Orexo covering North America....

  • OREXO/KYOWA HAKKO KIRIN DISTRIBUTE KW-2246 FOR CANCER PAIN.  // Worldwide Biotech;Mar2010, Vol. 22 Issue 3, p7 

    The article reports on the joint distribution agreement signed between Kyowa Hakko Kirin Co. Ltd. and pharmaceutical firm Hisamitsu Pharmaceutical Co. Inc. Kyowa will primarily handle the approval process for the product in Japan. Under the terms of the agreement, the two companies will jointly...

  • FDA Actions in brief.  // Managed Healthcare Executive;Feb2005, Vol. 15 Issue 2, p41 

    This article presents information on new drugs approved by the U.S. Food and Drug Administration (FDA). Pregabalin was approved for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. Darifenacin was approved for the treatment of...

  • Signals and Noise in Drug Safety Analyses. CEFALU, WILLIAM T.; ROSENSTOCK, JULIO; HENRY, ROBERT R.; RIDDLE, MATTHEW // Diabetes Care;Jul2013, Vol. 36 Issue 7, p1804 

    An introduction is presented in which the editor discusses various reports within the issue on topics including a commentary by Dr. Eric P. Brass on the vagueness of the input of advisory committees in the drug approval regulatory process and the need to understand the complexity of assessing...

  • Rx royalty looks lower for NU, prof. Merrion, Paul // Crain's Chicago Business;1/10/2005, Vol. 28 Issue 2, p3 

    This article reports that a new pain relief drug that once promised to be a home run is now looking more like a double for Northwestern University and Richard Silverman, the chemistry professor who invented it. Federal approval of pregabalin late last month came with a caveat that the drug must...

  • FDA Actions in brief.  // Managed Healthcare Executive;Apr2005, Vol. 15 Issue 4, p48 

    The article presents a brief account of the action taken by the Food and Drug Administration (FDA) of the United States, in response to applications made by various pharmaceutical companies for the approval of the respective drugs and medical products. A new dosage strength of the fentanyl...

  • Labopharm Shares Bounce Up as Path Emerges for Tramadol. Hollingsworth, Cathy // BioWorld Today;7/1/2008, Vol. 19 Issue 127, p5 

    The article reports on the statement by Labopharm Inc. that its painkiller tramadol could get a U.S. Food and Drug Administration (FDA) approval if it uses an analysis that the agency previously recommended. The statement has increased the company's stock price to 34.6 percent, to close at...

  • Pain Med Program Helps To Ensure Proper Use.  // RN;Jan2005, Vol. 68 Issue 1, p66 

    Reports on the United States Food and Drug Administration's approval of hydromorphone or Palladone for the treatment of moderate to severe pain in patients who need opioid pain relief for an extended period of time. Doses of the opioid drug available in the market; Risks associated with the use...

  • Suppressed study raises spectre of flawed drug regulation in US. Marris, Emma // Nature;12/2/2004, Vol. 432 Issue 7017, p537 

    Reports that the U.S. Food and Drug Administration is under increasing pressure to reform the way in which it monitors approved drugs. Suppression on the publication of a study into the safety of a painkiller, Withrawal of Vioxx, a prescription painkiller made by New Jersey-based Merck.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics